• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    QTREX Quantum (QTEX) Is Up 322.3% After $10M Private Placement And NYU Langone ART100 Order - What's Changed

    Simply Wall St·05/31/2026 00:13:30
    Listen to the news
    • QTREX Quantum Ltd., formerly Inspira Technologies Oxy B.H.N. Ltd., recently agreed to a US$10,000,000 private placement of 6,666,667 ordinary shares and earlier announced a US$580,000 commercial purchase order from NYU Langone Hospital for its FDA-cleared ART100 extracorporeal blood circulation systems.
    • Together with the upcoming ticker change to “QTEX” on the Nasdaq Capital Market, these moves highlight fresh institutional interest and early clinical adoption of the ART100 platform by a major U.S. hospital.
    • With the company’s recent share price gains, we’ll examine how the US$10,000,000 private placement shapes QTREX Quantum’s broader investment narrative.

    Uncover the next big thing with 23 elite penny stocks that balance risk and reward.

    What Is QTREX Quantum's Investment Narrative?

    For QTREX Quantum, the big-picture belief is that a tiny, loss-making company can turn its ART100 and AME platforms into meaningful commercial businesses while managing heavy dilution and execution risk. The US$10,000,000 private placement, alongside the NYU Langone US$580,000 order, slightly shifts the near-term focus: financing risk looks less acute, while proof-of-use at a major U.S. hospital gives the ART100 story more substance as a short term catalyst. At the same time, the capital raise adds to an already dilutive history at a company with less than US$1,000,000 in revenue and a very high price to book multiple, so expectations now need to be matched by delivery across both medtech and quantum connectivity initiatives.

    However, there is an important dilution and execution risk here that investors should be aware of. Our comprehensive valuation report raises the possibility that QTREX Quantum is priced higher than what may be justified by its financials.

    Exploring Other Perspectives

    QTEX 1-Year Stock Price Chart
    QTEX 1-Year Stock Price Chart
    The Simply Wall St Community’s two fair value estimates span US$1.43 to US$5.00, reflecting very different expectations. Set against QTREX’s fresh US$10,000,000 raise and limited revenues, these gaps underline why it helps to compare several independent viewpoints before drawing conclusions about the company’s potential.

    Explore 2 other fair value estimates on QTREX Quantum - why the stock might be worth as much as 63% more than the current price!

    Form Your Own Verdict

    Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your QTREX Quantum research is our analysis highlighting 4 important warning signs that could impact your investment decision.
    • Our free QTREX Quantum research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate QTREX Quantum's overall financial health at a glance.

    No Opportunity In QTREX Quantum?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.